BioLife Solutions (BLFS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

BioLife Solutions

NasdaqCM•Healthcare•Medical Instruments & Supplies

$35.25-0.28(-0.01%)Market closed

Market Cap

$1.73B

P/E

29.9x

P/S

16.8x

P/B

4.1x

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

How this company scores

GoodMetricSide Score: 60/100

Strongest: Growth (21/25); weakest: Cash & Earnings Quality (7/25).

Profitability17/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality7/25

Strengths

Growing revenueRising earningsInterest easily coveredProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 29.9x5y range 29.9x – 221.2x

P/S · 16.8x5y range 6.7x – 17.0x

Currently above its 20-quarter median.

P/B · 4.1x5y range 2.1x – 4.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -0.2x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $1.73B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $102.82M
Q. Revenue: $28.47M
TTM EBITDA: $5.13M
TTM Op. Income: $2.98M
Q. Op. Income: $1.70M
TTM Net Income: $57.98M
Q. Net Income: $45.10M
EPS: $0.92
Shares Out.: $48.87M

$102.82M in TTM revenue grew 43.7% YoY, reaching $28.47M last quarter. TTM EBITDA of $5.13M and TTM operating income of $2.98M show growth is flowing through to the bottom line. TTM net income of $57.98M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 64.2%
EBITDA Margin: 7.4%
Op. Margin: 6.0%
Net Margin: 158.4%

Op. margin of 6.0% is up 71.4% YoY — cost efficiency is improving. Net margin at 158.4% and gross margin of 64.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 109% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 29.9x
P/S Ratio: 16.8x
P/B Ratio: 4.1x

At 29.9x P/E, the stock trades within typical market levels. P/S of 16.8x and P/B of 4.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $447.49M
Cash: $24.00M
Long-Term Debt: N/A
Book Value: $420.00M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $6.35M
TTM Free Cash Flow: $8.11M
FCF Margin: 7.9%
FCF / Net Income: 0.1

TTM FCF of $8.11M on $6.35M in operating cash flow. The FCF / Net Income ratio of 0.1x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.